分析瑞舒伐他汀联合抗血小板药物治疗缺血性脑血管病的效果  

Analysis of the effect of rosuvastatin combined with antiplatelet drugs in the treatment of ischemic cerebrovascular disease

作　　者：王莉 WANG Li(Department of Neurology,Zhangjiagang Fifth People's Hospital,Zhangjiagang 215600,China)

机构地区：[1]张家港市第五人民医院神经内科,215600

出　　处：《中国现代药物应用》2025年第4期101-103,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨对缺血性脑血管病患者采用瑞舒伐他汀+抗血小板药物治疗的临床效果。方法选取62例缺血性脑血管病患者,以投掷硬币法为依据分为参照组(31例)和研究组(31例)。参照组采用抗血小板药物+阿托伐他汀治疗,研究组采用抗血小板药物+瑞舒伐他汀治疗。比较两组患者的治疗效果、美国国立卫生研究院卒中量表(NIHSS)评分、血液流变学指标以及超敏C反应蛋白水平。结果研究组患者治疗总有效率96.77%较参照组的74.19%更高(P<0.05)。治疗前,研究组患者NIHSS评分、红细胞比容、血浆粘度以及超敏C反应蛋白水平与参照组比较统计结果无差异(P>0.05);治疗后,研究组患者NIHSS评分(11.41±3.26)分及红细胞比容(40.19±6.25)%、血浆粘度(1.62±0.05)mPa·s、超敏C反应蛋白(3.53±1.29)mg/L均较参照组的(18.45±4.77)分、(46.39±5.41)%、(1.49±0.09)mPa·s、(8.39±1.26)mg/L更低(P<0.05)。结论缺血性脑血管病患者采用瑞舒伐他汀+抗血小板药物联合治疗,可明显提升患者用药效果,并且改善患者的神经功能等临床指标。Objective To explore the clinical effect of rosuvastatin combined with antiplatelet drugs in the treatment of ischemic cerebrovascular disease.Methods 62 patients with ischemic cerebrovascular disease were selected and divided into the reference group(31 cases)and the study group(31 cases)according to the coin-tossing method.The reference group was treated with antiplatelet drug+atorvastatin,and the study group was treated with antiplatelet drug+rosuvastatin.The therapeutic effect,National Institutes of Health Stroke Scale(NIHSS)score,hemorheological indicators and hypersensitive C-reactive protein level were compared between the two groups.Results The total effective rate of 96.77%in the study group was higher than 74.19%in the reference group(P<0.05).Before treatment,there was no significant difference in NIHSS score,hematocrit,plasma viscosity and hypersensitive C-reactive protein level between the study group and the reference group(P>0.05).After treatment,the study group had NIHSS score of(11.41±3.26)points,hematocrit of(40.19±6.25)%,plasma viscosity of(1.62±0.05)mPa·s and hypersensitive C-reactive protein of(3.53±1.29)mg/L,which were lower than(18.45±4.77)points,(46.39±5.41)%,(1.49±0.09)mPa·s and(8.39±1.26)mg/L in the reference group(P<0.05).Conclusion The combination of rosuvastatin and antiplatelet drugs in patients with ischemic cerebrovascular disease can significantly improve the therapeutic effect of patients,and improve the clinical indicators such as neurological function.

关 键 词：瑞舒伐他汀 抗血小板药物 缺血性脑血管病 神经功能 血液流变学 超敏C反应蛋白 

分 类 号：R743.3[医药卫生—神经病学与精神病学]